Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Oliver IlliniMaximilian Johannes HochmairHannah FabikanChristoph WeinlingerAmanda TufmanAurélie SwalduzKristina LambergSayed M S HashemiFlorian HuemerAnders VikströmMartin WermkeGudrun AbsengerAlfredo AddeoShantanu BanerjiAntonio CallesStephen ClarkeMassimo Di MaioAlice DurandMichaël DuruisseauxMalinda ItchinsOkko-Sakari KääränienFlorian KrennEckart LaackAdrianus Johannes de LangenKatja MohorcicGeorg PallAntonio PassaroGerald PragerAchim RittmeyerJeffrey RothensteinMichael SchumacherEwald WöllArschang ValipourPublished in: Therapeutic advances in medical oncology (2021)
In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated.